What is more satisfying than developing an innovative medication, all the way from your initial basic science to a medical application? Academic discoveries that are translated to the clinic improve patients’ quality of life and add value to healthcare systems around the world. For us, this is the real meaning of ‘giving back to society’.
Orionis Biosciences is today debuting with the announcement of a major drug discovery collaboration with Novartis. Orionis has developed innovative technologies in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities to tackle the industry’s most intractable disease targets.
Moving from scientific insight to innovative applications is not always an easy road to travel. Each year, the prestigious journal Nature Biotechnology compiles a list of twenty researchers who excel in navigating this challenging path. Jan Tavernier (VIB-UGent Center for Medical Biotechnology) is only the second Belgian ever, and one of the very few Europeans, to make it onto the US-dominated list. The list is an aggregate score of number of patents granted in that year, patent citations and h-index.
The labs of Jan Tavernier, Kris Gevaert and Sven Eyckerman from the VIB Medical Biotechnology Center, UGent tackle some of the most fundamental life sciences questions in their research into the detection and analysis of protein-protein interaction. This kind of analysis helps scientists come up with new hypotheses for the functions of proteins. Unfortunately, good data analysis in this area is tricky. Until now: Jan, Kris and Sven developed SFINX, a powerful online tool that does away with the hassle.